Verified employee & interview reviews

SRL Diagnostics Reviews

Mumbai, Maharashtra

5.0/ 5

1 review

Agilus Diagnostics Limited, formerly known as SRL Diagnostics Private Limited (and originally incorporated as Specialty Ranbaxy Limited), is a prominent Indian multinational diagnostics company providing comprehensive pathology and radiology services. Founded on July 7, 1995, as a joint venture between Ranbaxy Laboratories and US-based Specialty Laboratories, the company became the first pathology network in India to receive accreditation from the National Accreditation Board for Testing and Calibration Laboratories (NABL). Over the years, it went through several strategic rebrandings—becoming SRL Ranbaxy in 2001, Super Religare Laboratories in 2008, and SRL Diagnostics following its acquisition by Fortis Healthcare. In May 2023, the company officially rebranded to Agilus Diagnostics. The company's corporate headquarters is situated in Gurgaon, Haryana, with registered corporate entities listed in New Delhi. Agilus Diagnostics operates as a major public unlisted company, heavily backed by its majority owner, Fortis Healthcare, which holds a 57.68% stake, alongside key private equity investors including NYLIM, Resurgence PE, and the International Finance Corporation (IFC). Under the leadership of Managing Director and CEO Anand Kuppuswamy, the network serves patients across India, Dubai, Afghanistan, and Nepal. As one of India's largest diagnostic chains, the company manages an expansive infrastructure of over 418 laboratories and hundreds of wellness and collection centers. This massive footprint grew significantly after its ₹350 crore acquisition of Kerala-based DDRC Laboratories, which solidified its leadership in South India. Its core service segments encompass pathology—offering nearly 3,700 advanced screening tests ranging from routine hematology to high-end molecular pathology, cytogenetics, and histopathology—and cutting-edge radiology testing. Additionally, the company services specialized verticals including Central Laboratory Services for global clinical trials, structured Home Sample Collection systems, and customized preventive corporate healthcare packages. Operationally, the network runs on advanced technological platforms, utilizing fully automated analytical modules like the Cobas c 702 and VITEK MS MALDI-TOF technology to deliver faster, high-precision identification of pathogens within minutes. Financially, the company remains highly stable with an authorized share capital of ₹5.00 crore and a paid-up capital of ₹3.96 crore. For the fiscal year 2022, Agilus reported a robust consolidated revenue from operations of ₹1,605 crore and an operating income of ₹425 crore. To scale its market capture, the company segments its outreach models into specialized divisions including Clinic Lab Management (CLM), Hospital Lab Management (HLM), and Pathologist Lab Management (PLM), helping to integrate localized workflows with standardized national reporting. Embracing a patient-centric approach, the firm remains focused on driving public health outcomes through technology-driven diagnostics.